Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
Crunch time approaches for UroGen.
Lilly, Merck & Co and Verastem could take on Amgen, Bristol and Revolution.
Meanwhile, Pfizer reckons it's found the right dose for its KAT6.
Petosemtamab and ficerafusp alfa are among the biologicals to be featured at ASCO.
Roche’s PI3Kα inhibitor continues to pull away from Novartis’s Piqray.
Herthena-Lung02 data are an ASCO shocker.
